N-(1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-2,2,2-trifluoroacetamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: N-(1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-2,2,2-trifluoroacetamide
• 英文别名: N-(1,3-dioxoisoindol-5-yl)-2,2,2-trifluoroacetamide
• 化学式: C₁₀H₅F₃N₂O₃
• 分子量: 258.15
• InChiKey: NOIHKIDAFYJJSH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  75.3
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• [EN] COMPOUNDS WITH PGD2 ANTAGONIST ACTIVITY<br/>[FR] COMPOSES A ACTIVITE ANTAGONISTE DE PGD2
  申请人：OXAGEN LTD

  公开号：WO2005040112A1

  公开（公告）日：2005-05-06

  Compounds of general formula (I); wherein R1, R2, R3 and R4 are independently hydrogen, halo, -C1-C6 alkyl, -O(C1-C6 alkyl), -C1-C6 alkyl(C3-C7 cycloalkyl), -CON(R9)2, -SOR9, -S02R9. -S02N(R9)2, -N(R9)2, -NR9OR9, -C02R9, COR9, -SR9, -OH, -N02 or -CN; each R9 independently hydrogen or C1-C6 alkyl; R5 and R6 are each independently hydrogen, or C1-C6 alkyl or together with the carbon atom to which they are attached form a C3-C7 cycloalkyl. group; R7 is hydrogen or C1-C6 alkyl; R8 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl or an aromatic moiety, any of which may optionally be substituted with one or more substituents selected from halo, -SOR13 -S02R13, -R14, -OR14, -CON(R14)2 -SOR14, -S02R14, -S02N(R14) -SO2N(R14)2, -N(R 14)2, NR14COR14, -CO2R14, COR14, -SR14, -N02 or -CN; wherein R13 is a 5 to 7 membered heterocyclic ring; and each R14 is independently hydrogen, alkyl or aryl, the aryl being optionally substituted by -R9, -OR9, -CON(R9)2, -SOR9 -S02R9, -S02N(R9)2, -N(R9)2, NR9COR9, -C02R9, -COR9, -SR9, halo, -N02 or -CN; wherein R9 is as defined above; provided that when R1 , R3 and R4 are hydrogen and R2 is hydrogen, halogen or -O(C1-C6)alkyl, R8 is not unsubstituted phenyl or phenyl substituted by halo, C1-C6 alkyl, -O(C1-C6)alkyl, -S(C1-C6)alkyl or -CO(C1-C6)alkyl; or pharmaceutically acceptable salts, hydrates, solvates, compexes or prodrugs therof are useful in the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.

  通式（I）的化合物；其中R1、R2、R3和R4独立地是氢、卤素、-C1-C6烷基、-O(C1-C6烷基)、-C1-C6烷基(C3-C7环烷基)、-CON(R9)2、-SOR9、-S02R9、-S02N(R9)2、-N(R9)2、-NR9OR9、-C02R9、COR9、-SR9、-OH、-N02或-CN；每个R9独立地是氢或C1-C6烷基；R5和R6独立地是氢或C1-C6烷基，或者与它们连接的碳原子一起形成一个C3-C7环烷基基团；R7是氢或C1-C6烷基；R8是C1-C6烷基、C2-C6烯基、C2-C6炔基或芳香基，其中任何一个可以选择地被一个或多个卤素、-SOR13、-S02R13、-R14、-OR14、-CON(R14)2、-SOR14、-S02R14、-S02N(R14)、-SO2N(R14)2、-N(R14)2、NR14COR14、-CO2R14、COR14、-SR14、-N02或-CN的取代基取代；其中R13是一个含有5至7个成员的杂环；每个R14独立地是氢、烷基或芳基，芳基可以选择地被-R9、-OR9、-CON(R9)2、-SOR9、-S02R9、-S02N(R9)2、-N(R9)2、NR9COR9、-C02R9、-COR9、-SR9、卤素、-N02或-CN取代；其中R9如上所定义；但是当R1、R3和R4是氢且R2是氢、卤素或-O(C1-C6)烷基时，R8不是未取代的苯基或被卤素、C1-C6烷基、-O(C1-C6)烷基、-S(C1-C6)烷基或-CO(C1-C6)烷基取代的苯基；或者其药学上可接受的盐、水合物、溶剂合物或前药在治疗过敏性疾病，如哮喘、过敏性鼻炎和特应性皮炎中有用。
• Phthalimide compounds useful as protein kinase inhibitors
  申请人：Green Jeremy

  公开号：US20050182061A1

  公开（公告）日：2005-08-18

  The present invention provides compounds as inhibitors of protein kinase, particularly inhibitors of AKT, PDK1, p70S6K, or ROCK kinase, mammalian protein kinases involved in proliferative and neurodegenerative disorders. The invention also provides processes for preparing the compounds of the invention, pharmaceutical compositions comprising the compounds, and methods of utilizing those compounds and compositions in the treatment of various disorders.

  本发明提供了作为蛋白激酶抑制剂的化合物，特别是AKT、PDK1、p70S6K或ROCK激酶的抑制剂，这些哺乳动物蛋白激酶参与了增殖性和神经退行性疾病。本发明还提供了制备本发明化合物的工艺、包含本发明化合物的药物组合物，以及利用这些化合物和组合物治疗各种疾病的方法。
• [EN] PHTHALIMIDE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS<br/>[FR] COMPOSES PHTALIMIDE UTILES EN TANT QU'INHIBITEURS DE PROTEINE KINASE
  申请人：VERTEX PHARMA

  公开号：WO2005039564A1

  公开（公告）日：2005-05-06

  The present invention provides compounds of formula I as inhibitors of protein kinase, particularly inhibitors of AKT, PDK1, p70S6K, or ROCK kinase, mammalian protein kinases involved in proliferative and neurodegenerative disorders. The invention also provides processes for preparing the compounds of the invention, pharmaceutical compositions comprising the compounds, and methods of utilizing those compounds and compositions in the treatment of various disorders.